CN1301709C - Skin plaster containing aceclofenac - Google Patents
Skin plaster containing aceclofenac Download PDFInfo
- Publication number
- CN1301709C CN1301709C CNB2005100084012A CN200510008401A CN1301709C CN 1301709 C CN1301709 C CN 1301709C CN B2005100084012 A CNB2005100084012 A CN B2005100084012A CN 200510008401 A CN200510008401 A CN 200510008401A CN 1301709 C CN1301709 C CN 1301709C
- Authority
- CN
- China
- Prior art keywords
- aceclofenac
- weight portions
- patch
- weight
- sensitive adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to plaster containing aceclofenac, which is used for skin. Particularly, the present invention is skin part application plaster of aceclofenac medicine used for treating and releasing osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and sciatica.
Description
Technical field
The present invention relates to a kind of novel form of nonsteroidal anti-inflammatory drug, a kind of a kind of local skin patch that is used for the treatment of with the medicine aceclofenac of relief from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, sciatica of more specifically saying so.
Background technology
Aceclofenac (aceclofenac) is a kind of NSAID (non-steroidal anti-inflammatory drug), chemistry [neighbour-(2, the 6-dichloroaniline) benzene] acetoacetic acid by name, and 1992 first by the exploitation listing of Spain Pu Ludesi drugmaker.Aceclofenac is the derivant of diclofenac sodium, ooze out by the biosynthesis of the scorching pain of inhibition epoxidase reduction position prostaglandin and by inflammatory mediators such as inhibition lipoxygenase reduction leukotriene, Kallidin Is, alleviate partial inflammatory reaction, the congested swelling of tissue, the mediator that reduces inflammation causes the sensitization that inflammation causes pain, thereby produces anti-inflammatory and analgesic effect.Because it has obviously analgesia, the refrigeration function of antiinflammatory, brute force widely, is applicable to the various rheumatic arthritis of treatment, rheumatoid arthritis, osteoarthritis and spondylitis, also is applicable to pain and heating that various diseases causes.Its biological half-life is long than diclofenac, and gastrointestinal tolerance is good than diclofenac, and anti-inflammatory activity and is better than naproxen and Phenylbutazone similarly, is treatment acute and chronic pain, antiphlogistic safe and reliable medicine.Main in the market dosage form has oral administered dosage forms such as tablet, capsule.The aceclofenac oral absorption is complete rapidly, reaches maximum plasma concentration in 1.25～3 hours, occurs untoward reaction such as gastrointestinal upset, dizziness, liver enzyme rising, pruritus simultaneously.It is aceclofenac ointment (China Medicine University's journal of substrate with the Polyethylene Glycol that bibliographical information has been arranged, 1996,27 (12): 718～721), also had bibliographical information diclofenac sodium and aceclofenac solution transdermal test in vitro Absorption Study (China Medicine University's journal, 2004,35 (4): 311～314), but the composition of aceclofenac preparation capable of permeating skin is not studied, also do not reported the composition of aceclofenac skin plaster agent.
Summary of the invention
Aceclofenac is oral to have zest to gastrointestinal tract, the present invention finds unexpectedly, aceclofenac is made the skin plaster agent can make better effect of aceclofenac performance, simultaneously through the prescription screening, found a kind of safe and effective especially, side effect is little, particularly reduce irritating aceclofenac skin plaster agent prescription.
Aceclofenac skin plaster of the present invention agent can be a rapid release, also can be slow release, is made up of pastille casing play, backing layer, anti-glutinous layer.
Contain aceclofenac and pressure sensitive adhesive in the pastille casing play of skin plaster agent of the present invention, can add some auxiliary elements in case of necessity.
The content range of the aceclofenac in the pastille casing play is 0.1%～20% by weight percentage.This percentage by weight is that the percentage calculation that the amount with aceclofenac accounts for the total formulation weight amount obtains, and described total formulation weight amount does not comprise the weight that medicine is played the backing layer of supporting role.
Pressure sensitive adhesive in the pastille casing play (be called for short PSAs) means can produce under light pressure and adheres to and do not have the class sticky polymers that residue stays when removing.Mainly be used on the pharmaceutical adhesive preparation, can have bought on the market, belong to prior art.The basic composition of pressure sensitive adhesive is: be base material with the long-chain polymer, add tackifying resin and softening agent and make.Long-chain polymer can be natural rubber, polyisoprene rubber, reclaimed rubber, butadiene-styrene rubber, butyl rubber, acrylonitrile-butadiene rubber, polyvinylether, ethylene or more senior ether, polyacrylate and copolymer thereof etc.Cohesiveness, stability and non-oxidizability be can, to improve in order improving liquidity, some filleies and antiaging agent etc. often to be needed to add.Usually polymer is called pressure sensitive adhesive, other be called additive.The general pressure sensitive adhesive that is called also can mix all components.
Pressure sensitive adhesive in the aceclofenac patch of the present invention is selected from: rubber-like pressure sensitive adhesive, polyacrylate pressure sensitive adhesive, polyacrylic resin class pressure sensitive adhesive, content range are 40-98% by weight percentage.These different classes of pressure sensitive adhesives are to be made by natural rubber, Oppanol, polyisoprene rubber, butadiene-styrene rubber and their reclaimed rubber, polyacrylate, polyacrylic resin class material.
The auxiliary element that can add described in the pastille casing play is selected from: one or more in plasticizer, tackifier, the drug transdermal absorption enhancer.
The plasticizer that adds can be in mineral oil, decanedioic acid diethyl (fourth) ester, diethyl phthalate, triethyl citrate and other preparation process plasticizer that allows to add one of or both or both the above mixture between them;
In the tackifier that the tackifier that adds can be the multicomponent organic acid that comprises succinic acid, citric acid, other preparation process of Colophonium allows to add one of or both or both the above mixture between them;
The drug transdermal absorption enhancer that adds can be one of oleic acid, laurocapram (Azone), Oleum menthae, eucalyptus oil or both or both the above mixture between them.
The backing layer of skin plaster agent of the present invention is that ingredient is coated with in the above, and medicine is played the part of supporting role, can be any in non-woven fabrics, cotton, stationery, polychloroethylene film, polyethylene film, the polyester film.
The anti-glutinous layer of skin plaster agent of the present invention can be any in the paper that scribbles silicone oil, polychloroethylene film, polyethylene film, the polyester film, plays a part the medicine layer that protection has viscosity.
Skin plaster agent of the present invention through screening, has been found preferred prescription, and wherein preferred prescription comprises:
Contain in the pastille casing play: aceclofenac, polyacrylate (or polyacrylic resin), decanedioic acid diethyl (fourth) ester (or triethyl citrate), laurocapram (or Oleum menthae), succinic acid (or citric acid).
Backing layer is non-woven fabrics, cotton, polyester film;
Anti-glutinous layer is the paper that scribbles silicone oil.
Write out a prescription (percetage by weight) composed as follows:
Aceclofenac 1-20%
Polyacrylate (or polyacrylic resin) 40-98%
Decanedioic acid diethyl (fourth) ester (or triethyl citrate) 0-20%
Laurocapram (or Oleum menthae) 1-10%
Succinic acid (or citric acid) 0-10%
Particularly preferred prescription is
Contain in the pastille casing play: contain in the pastille casing play: aceclofenac, polyacrylate, decanedioic acid diethyl (fourth) ester, laurocapram.
Backing layer is non-woven fabrics, cotton, polyester film;
Anti-glutinous layer is the paper that scribbles silicone oil.
Write out a prescription (percetage by weight) composed as follows:
Aceclofenac 5-20%
Polyacrylate 65-94%
Decanedioic acid diethyl (fourth) ester 0-10%
Laurocapram 1-5%
Most preferred prescription is:
Write out a prescription (percetage by weight) composed as follows::
Aceclofenac 10%
Polyacrylate 80%
Decanedioic acid diethyl (fourth) ester 5%
Laurocapram 5%
The present invention also comprises the preparation method of skin plaster agent of the present invention, this method comprises: pressure-sensitive adhesive material is dissolved in the volatile solvent, with medicine aceclofenac dissolving or be dispersed in the pressure sensitive adhesive solution, then mixed solution is coated on backing layer or the anti-glutinous layer with suitable technology, the drying and volatilizing solvent covers anti-glutinous layer or backing layer.According to the needs of dosage or agents area, cut into circle, ellipse, square, rectangle or other irregular shape.
Skin plaster agent of the present invention can be used for diseases such as treatment and relief from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, sciatica.
Skin plaster agent of the present invention in use can be with reference to following method:
The affected part is cleaned, dried, patch of the present invention directly is affixed on the affected part gets final product, according to the state of an illness or doctor's advice, the inferior or number subsides of subsides in a day.
Following data by experiment illustrate advantage of the present invention:
The stripped nude mice skin permeability test of warp: with stripped nude mice skin is model, adopts conventional vertical diffusion cell to experimentize.Corium Mus is fixed between two and half ponds of vertical diffusion cell with clip, cuticular one side is arranged towards the donor pond.On the cuticular one side of having of Corium Mus, stick the patch of preparation of the present invention.The phosphate buffer that in the receptor pond, adds 13mlpH6.8.Whole device places 32 ± 1 ℃ of water-baths.Respectively at 1,2,3,4,5,6,7,8 hour timing sampling, sample volume was 1ml, replenished the phosphate buffer of isopyknic blank pH6.8 simultaneously.Sample application HPLC method is measured concentration, calculates steady state flow (μ gcm
-2H
-1).
| Embodiment | Steady state flow (μ gcm -2·h -1) |
| Embodiment 1 embodiment 3 embodiment 6 embodiment 12 | 8.59 15.21 20.06 19.09 |
By steady state flow (the μ gcm in the table
-2H
-1) measurement result as can be seen, the aceclofenac patch of the present invention preparation has the good penetration effect external through nude mice skin.
Skin plaster agent of the present invention is compared following advantage with other dosage form of aceclofenac: (1) avoids the untoward reaction that brings because of oral formulations; (2) through affected part, raising local blood concentration; (3) be particularly suitable for the inconvenient patient of oral administration; (4) blood drug level is steady, and long action time does not need frequent administration; (5) overcoming ointment formulation is difficult to accurately control dosage, uses shortcomings such as inconvenience, pollution clothes; (6) to the body not damaged, zest is little.Aceclofenac skin plaster of the present invention agent, can make the medicine affected part of going directly, improve the local organization drug level, help the local positioning treatment of pathological tissues, reduce whole body blood drug level, overcome the untoward reaction that such drug oral causes, also have advantages such as long-acting, slow release, also overcome simultaneously ointment formulation and be difficult to accurately control dosage, use shortcomings such as inconvenience, pollution clothes, pasted firmly, skin nonirritant and sensitization.Patch medicine of the present invention exists with dissolved state, and its percutaneous rate is fast; Preparation stabilization, wild effects such as the no crystallize of long-term placement take place.
The specific embodiment
Now in conjunction with the embodiments, a kind of skin plaster agent that contains aceclofenac of the present invention is described in detail.
Embodiment 1: the method for making that with the Oppanol is the patch that contains aceclofenac of skeleton: get polyisobutylene and poly-isobutyl group butadiene mixture 100 weight portions, be dissolved in the 400 weight portion chloroforms, add aceclofenac 5 weight portions, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 2: the method for making that with the polyisoprene rubber is the skin plaster agent that contains aceclofenac of skeleton: get polyisoprene and poly-isobutyl group butadiene mixture 100 weight portions, be dissolved in the 400 weight portion chloroforms, add aceclofenac 28 weight portions, 6 parts of mineral oil weight, triethyl citrate 2 weight portions, diethyl phthalate 1 weight portion, 5 parts of citric acid weight, Oleum menthae 3 weight portions, eucalyptus oil 2 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 3: the method for making that with the acrylate pressure-sensitive adhesive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% acrylate pressure-sensitive adhesive (ethyl acetate is a solvent) 100 weight portions, add aceclofenac 5 weight portions, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 4: the method for making that with butadiene-styrene rubber is the patch that contains aceclofenac of skeleton; Get polyisobutylene and poly-isobutyl group butadiene mixture 100 weight portions, Colophonium 5 weight portions are dissolved in the 400 weight portion chloroforms, add aceclofenac 1 weight portion, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 5: the method for making that with the acrylate pressure-sensitive adhesive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% acrylate pressure-sensitive adhesive (ethyl acetate is a solvent) 100 weight portions, add 15 parts of aceclofenac weight, decanedioic acid diethyl (fourth) ester 12 weight portions, Colophonium 4 weight portions, succinic acid 3 weight portions, oleic acid 5 weight portions, Oleum menthae 3 weight portions, eucalyptus oil 3 weight portions, dissolving is uniformly dispersed, coating, drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 6: the method for making that with the acrylate pressure-sensitive adhesive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% acrylate pressure-sensitive adhesive (ethyl acetate is a solvent) 100 weight portions, add aceclofenac 5 weight portions, oleic acid 3 weight portions, dissolving is uniformly dispersed, coating, drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 7: the method for making that with the polyacrylate pressure-sensitive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% pressure sensitive adhesive (ethyl acetate is a solvent) 800 weight portions, add aceclofenac 0.3 weight portion, mineral oil 36 weight portions, Colophonium 26 weight portions, laurocapram 43 weight portions, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 8: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin IV100 weight portion, be dissolved in the alcohol solvent of 200 weight portions, add aceclofenac 10 weight portions, decanedioic acid diethyl (fourth) ester 15 weight portions, diethyl phthalate 10 weight portions, citric acid 6 weight portions, succinic acid 4 weight portions, laurocapram 7 weight portions, eucalyptus oil 3 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 9: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic acid tree II100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 5 weight portions, triethyl citrate 30 weight portions, succinic acid 8 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 10: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin III100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 1 weight portion, triethyl citrate 40 weight portions, dissolving is uniformly dispersed, and films solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 11: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin IV100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 5 weight portions, triethyl citrate 20 weight portions, decanedioic acid diethyl (fourth) ester 12 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 12: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin IV100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 15 weight portions, triethyl citrate 20 weight portions, decanedioic acid diethyl (fourth) ester 12 weight portions, succinic acid 5 weight portions, laurocapram 3 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 13: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin IV100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 1 weight portion, triethyl citrate 20 weight portions, decanedioic acid diethyl (fourth) ester 12 weight portions, succinic acid 5 weight portions, oleic acid 8 weight portions, dissolving is uniformly dispersed, film, solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 14: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic resin IV100 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 26 weight portions, triethyl citrate 12 weight portions, decanedioic acid diethyl (fourth) ester 7 weight portions, citric acid 5 weight portions, succinic acid 3 weight portions, Colophonium 2 weight portions, laurocapram 3 weight portions, Oleum menthae 2 weight portions, dissolving is uniformly dispersed, and films solvent flashing, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 15: the method for making that with the acrylate pressure-sensitive adhesive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% acrylate pressure-sensitive adhesive (ethyl acetate is a solvent) 100 weight portions, add aceclofenac 10 weight portions, decanedioic acid diethyl (fourth) ester 16 weight portions, succinic acid 8 weight portions, oleic acid 5 weight portions, laurocapram 10 weight portions, dissolving is uniformly dispersed, coating, drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 16: with the polyacrylic resin pressure sensitive adhesive is the method for making that skeleton contains the patch of aceclofenac; Get polyacrylic acid tree II500 weight portion, be dissolved in the ethanol and acetone mixed solvent of 200 weight portions, add aceclofenac 5 weight portions, decanedioic acid diethyl (fourth) ester 2 weight portions, laurocapram 3 weight portions, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Embodiment 17: the method for making that with the acrylate pressure-sensitive adhesive is the patch that contains aceclofenac of skeleton; Get solid content and be 30% acrylate pressure-sensitive adhesive (ethyl acetate is a solvent) 100 weight portions, add aceclofenac 8 weight portions, decanedioic acid diethyl (fourth) ester 8 weight portions, diethyl phthalate 5 weight portions, citric acid 5 weight portions, succinic acid 5 weight portions, laurocapram 5 weight portions, dissolving is uniformly dispersed, coating, the drying and volatilizing solvent, combination backing layer, anti-glutinous layer, requirement cuts into the patch of suitable size according to dosage.
Aceclofenac patch according to embodiment 2 makes has carried out Preliminary Clinical Observation, and the patient is rheumatoid arthritis (Rheumatoid Arthritis, patient RA), case load 30 people, 2 months observing times.The diagnosis of RA according to the standard of American Rheumatism Association (ARA) with the patient be divided into active stage, two or three functions/dissection rank are disconnected, have six all joints symptoms at least.Got rid of the person that has the severe complication, stomach or duodenal ulcer active stage person, small intestinal absorbs syndrome, the moderate renal insufficiency (inulin clearance≤70ml/min), serious hepatic insufficiency person, just taking steroid hormone, anticoagulant, barbiturate, sulfonylurea drugs person, to being subjected to reagent thing allergy sufferers, anemia of pregnant woman and women breast-feeding their children or the like.The curative effect parameter has (1) VAS; (2) Ritchie parameter; (3) grip; (4) function of joint (0=is normal, 1=proper motion pain, the 2=limitation of movement, 3=can not move); (5) ankylosis time span in morning (0=does not have, and 1=was less than 30 minutes, and 2=30 minute to 2 hours, 3=was above 2 hours).The result shows: paste every day 1～2, is affixed on the joint of getting involved, and patient's symptom of 92.6% is improved, and the state of an illness has obtained effective control, and onset is the fastest, and analgesic activity is strong, and better tolerance is non-stimulated to skin, and other untoward reaction does not take place yet.
Aceclofenac patch according to embodiment 12 makes has carried out preliminary clinical observation, and the patient is by WHO or European standard or radiodiagnosis and confirms to suffer from the patient that bone closes tuberosity inflammation (Osteoarthritis OA).Case load 28 people, 1 month course of treatment, dosage: every day 1～2 pastes, and is affixed on the patient joint of getting involved.The index of curative effect: the pain (0=does not have pain for VAS distance, 0-100cm, the intolerable pain of 100=) the when pain during rest, motion or pressurized; Press the SIG index or press pain degree and function synthesized index evaluation arthritis severity; Bending of knee (FLEX) and stretching, extension (EXT) are used to estimate the function in joint.Simultaneously, check patient's blood and urine, in time other side effect of record patient.The result shows: the aceclofenac patch is at alleviating pain and improve and have good effect aspect the function of joint, and is non-stimulated to skin, better tolerance, the untoward reaction that no oral formulations causes.
Claims (5)
1. skin plaster agent that contains aceclofenac is made up of pastille casing play, backing layer, anti-glutinous layer, wherein contains following components in weight percentage in the pastille casing play:
Aceclofenac 1-20%
Polyacrylate or polyacrylic resin 40-98%
Ethyl sebacate 0-20%
Laurocapram 1-10%
Succinic acid 0-10%.
2. patch according to claim 1 is characterized in that, wherein component that contains in the pastille casing play and their percentage by weight are as follows,
Aceclofenac 5-20%
Polyacrylate 65-94%
Ethyl sebacate 0-10%
Laurocapram 1-5%.
3. patch according to claim 1 is characterized in that, wherein component that contains in the pastille casing play and their percentage by weight are as follows,
Aceclofenac 10%
Polyacrylate 80%
Ethyl sebacate 5%
Laurocapram 5%.
4. patch according to claim 1 is characterized in that, anti-glutinous layer is selected from: the paper, polychloroethylene film, polyethylene film, the polyester film that scribble silicone oil; Backing layer is selected from: non-woven fabrics, cotton, stationery, polychloroethylene film, polyethylene film, polyester film.
5. patch according to claim 1 is characterized in that: described patch is circle, ellipse, square, rectangle or other irregular shape.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100084012A CN1301709C (en) | 2005-02-17 | 2005-02-17 | Skin plaster containing aceclofenac |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100084012A CN1301709C (en) | 2005-02-17 | 2005-02-17 | Skin plaster containing aceclofenac |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682705A CN1682705A (en) | 2005-10-19 |
| CN1301709C true CN1301709C (en) | 2007-02-28 |
Family
ID=35262326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100084012A Expired - Fee Related CN1301709C (en) | 2005-02-17 | 2005-02-17 | Skin plaster containing aceclofenac |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301709C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369116B2 (en) * | 2015-03-02 | 2019-08-06 | Hisamitsu Pharmaceutical Co., Inc. | Patch comprising an adhesive layer having a nonfunctional silicone oil |
| CN109125733A (en) * | 2018-10-30 | 2019-01-04 | 成都先手生物科技有限公司 | A kind of composition for the treatment of of arthritis and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1451380A (en) * | 2002-04-19 | 2003-10-29 | 北京德众万全药物技术开发有限公司 | Percutaneous tobuterol patch |
| CN1543359A (en) * | 2001-07-03 | 2004-11-03 | �Ƚ�����ҩ���о���˾ | Compositions and preparation methods for bioavailable oral aceclofenac dosage forms |
| CN1557320A (en) * | 2004-02-09 | 2004-12-29 | 沈阳药科大学 | Meloxicam containing skin topical paste formulation |
-
2005
- 2005-02-17 CN CNB2005100084012A patent/CN1301709C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543359A (en) * | 2001-07-03 | 2004-11-03 | �Ƚ�����ҩ���о���˾ | Compositions and preparation methods for bioavailable oral aceclofenac dosage forms |
| CN1451380A (en) * | 2002-04-19 | 2003-10-29 | 北京德众万全药物技术开发有限公司 | Percutaneous tobuterol patch |
| CN1557320A (en) * | 2004-02-09 | 2004-12-29 | 沈阳药科大学 | Meloxicam containing skin topical paste formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682705A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0062682B1 (en) | Adhesive preparation for heart disease and process for its preparation | |
| CN1204879C (en) | Transdermal therapeutic system with neutralized pressure sensitiivty acrylic adhesive patch | |
| RU2401126C2 (en) | Polymer adhesion matrix with carboxyl groups, forming salts for transdermal administration | |
| KR20030080070A (en) | Patch agent | |
| JPH0794394B2 (en) | Anti-inflammatory analgesic external patch | |
| CN110787150A (en) | A skin external preparation containing flurbiprofen | |
| EP2491924B1 (en) | Water-based paste containing diclofenac sodium | |
| JPH0725669B2 (en) | Pharmaceutical formulation for transdermal administration | |
| CN1215838C (en) | Diclofenac sodium pastes and preparation thereof | |
| CN1301709C (en) | Skin plaster containing aceclofenac | |
| CN1647803A (en) | Chinese medicine composition plaster for external anti-inflammation and analgetics | |
| CN103040792B (en) | Substrate of traditional Chinese medicine cataplasm | |
| CN1180770C (en) | Transdermal plaster of aryl propionic non-steroid antiphlogistic | |
| CN102949450B (en) | Nux vomica alkaloid patch for treating local myalgia and arthralgia and preparation method | |
| CN1565523A (en) | Percutaneous plaster and its preparation method | |
| CN101077343A (en) | Dexibuprofen granule and preparation method thereof | |
| CN1927191A (en) | Lornoxicam transdermal drug administration plaster and its preparation method | |
| CN106924223B (en) | Meloxicam patch and preparation method and application thereof | |
| JP4705343B2 (en) | Base for percutaneous absorption preparation and skin patch preparation using the same | |
| CN1613463A (en) | External applied Chinese medicinal paste for treating arthralgia | |
| CN1833715A (en) | Skin care gel for skin titillation and prepn. thereof | |
| CN1174031A (en) | Diclofenac sodium skin-penetrating delayed plaster | |
| CN104706725A (en) | Compound red sage root transdermal absorption patch and preparation method thereof | |
| CN100477994C (en) | Meloxicam containing skin topical paste formulation | |
| CN102652018A (en) | Felbinac-containing transdermal absorption preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070228 Termination date: 20140217 |